Who to call at Vera Therapeutics, Inc., and when
Fundz watches for the moments Vera Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Vera Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Vera Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vera Therapeutics, Inc.. With Fundz connected, it knows.
Vera Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
veratx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Vera Therapeutics appointed James R. Meyers as a Class II director, effective November 25, 2025, and to its Audit Committee. The grant package includes a 25,000-share option award, cash retainers, and eligibility for future annual option grants, which is a routine governance addition.
Key Takeaways
James R. Meyers joined the Board as a Class II Director effective November 25, 2025, with an initial term ending at the 2026 Annual Meeting of Stockholders.
Meyers was also appointed to the Audit Committee, effective on the same date as his Board appointment.
3 more takeaways
Related Filings (8)
8 more filings from Vera Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Vera Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.